ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Rating of “Moderate Buy” by Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $173.00.

Several research firms recently commented on ICUI. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Jefferies Financial Group initiated coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price target on the stock. KeyCorp boosted their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Finally, Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th.

Insiders Place Their Bets

In related news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $171.84, for a total value of $2,062,080.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,973,261.12. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,502 shares of company stock valued at $6,573,496 in the last quarter. Insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hexagon Capital Partners LLC lifted its holdings in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 122 shares during the period. Allworth Financial LP lifted its position in shares of ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 100 shares in the last quarter. Innealta Capital LLC purchased a new stake in ICU Medical during the 2nd quarter valued at approximately $32,000. Venturi Wealth Management LLC increased its holdings in ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 302 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of ICU Medical in the third quarter worth about $72,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Performance

ICUI stock opened at $168.46 on Monday. ICU Medical has a 12-month low of $83.26 and a 12-month high of $196.26. The business has a 50 day moving average of $176.22 and a 200-day moving average of $145.72. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The firm has a market cap of $4.12 billion, a PE ratio of -36.86 and a beta of 0.66.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.